Stocks Health care OVID
NASDAQ · Health careOvid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc. brought in $1.6M of revenue over the twelve months to June 30, 2026, down 76.2% from a year earlier. It posted a net loss of $34.5M. In fiscal 2025 capital spending exceeded operating cash flow by $38.3M. At June 30, 2026 it held $11.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What Ovid Therapeutics Inc. does
Ovid Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker OVID.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $7.3M | -$17.4M | n/a | -$38.3M |
| 2024 | $566K | -$26.4M | n/a | -$56M |
| 2023 | $392K | -$52.3M | -$0.74 | -$45.8M |
| 2022 | $1.5M | -$54.2M | -$0.77 | -$56.5M |
| 2021 | $208.4M | $122.8M | $1.76 | $118.4M |
| 2020 | $12.6M | -$81M | -$1.39 | -$51.7M |
Latest SEC filings
What Ovid Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- August 13, 2026Exhibits 8-K
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- July 8, 2026
- June 11, 2026
Questions about OVID
What does Ovid Therapeutics Inc. do?
Ovid Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker OVID.
Is Ovid Therapeutics Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $34.5M on revenue of $1.6M.
How much revenue does Ovid Therapeutics Inc. make?
Over the twelve months to June 30, 2026 Ovid Therapeutics Inc. reported revenue of $1.6M. That is 76.2% less than a year earlier.
When did Ovid Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the planned insider sale from August 24, 2026.
Similar companies
Follow OVID
Get an email when Ovid Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow OVID: get an email when it filesWhere the numbers come from
Financial figures are the values Ovid Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.